Priorities for rapid and cost-effective vaccines to improve outbreak responses
Gilbert SC., (2025), PLOS Biology, 23, e3003114 - e3003114
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.
Vatzia E. et al, (2024), NPJ vaccines, 9
Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
Wee EG-T. et al, (2024), Vaccines, 12, 965 - 965
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS pathogens, 20
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease
Drury RE. et al, (2024), Nature Communications, 15
Predicting airway immune responses and protection from immune parameters in blood following immunization in a pig influenza model.
Gubbins S. et al, (2024), Frontiers in immunology, 15
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nature communications, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Kaplonek P. et al, (2023), Nature immunology
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Hotez PJ. et al, (2023), BMJ global health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Excler J-L. et al, (2023), BMJ global health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Privor-Dumm L. et al, (2023), BMJ global health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Zhang P. et al, (2023)
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Vatzia E. et al, (2023), NPJ Vaccines, 8
Optimization of Molecular Methods for Detecting Duckweed-Associated Bacteria
Acosta K. et al, (2023), Plants, 12
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
McMahon WC. et al, (2023), AIDS (London, England), 37, 105 - 112
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
van Doremalen N. et al, (2022), NPJ vaccines, 7
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
Cable J. et al, (2022), Annals of the New York Academy of Sciences
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
van Doremalen N. et al, (2022), Nature Communications, 13
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Alharbi NK. et al, (2022), Vaccines, 10
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128
Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
Evans TG. et al, (2022), The Lancet. Infectious diseases, 22, 857 - 866
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe A. et al, (2022), JCI Insight, 7
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility
Rosadas C. et al, (2022), Journal of Virological Methods, 302, 114475 - 114475
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Sharpe HR. et al, (2022), JCI Insight, 7
Auxin-Producing Bacteria from Duckweeds Have Different Colonization Patterns and Effects on Plant Morphology
Gilbert S. et al, (2022), Plants, 11
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
van Doremalen N. et al, (2022), Res Sq
The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.
Utrilla-Trigo S. et al, (2022), Journal of virology, 96
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Lambe T. et al, (2021), Communications Biology, 4
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice
Collins KA. et al, (2021), Scientific Reports, 11
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
Fischer RJ. et al, (2021), Nature communications, 12
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens SAC. et al, (2021), Nature Communications, 12